Browse News
Filter News
Found 1,589 articles
-
Research continues to reveal how COVID-19 affects different people with different health issues, both short-term and long-term.
-
The U.S. Centers for Disease Control and Prevention (CDC) reported that the Omicron variant of COVID-19 had been identified in California.
-
The FDA’s Antimicrobial Drugs Advisory Committee voted 13 to 10 to recommend emergency authorization of molnupiravir.
-
It may take two to four weeks before experts have enough data to know whether Omicron is a bigger threat than Delta. Much of what is known is based on lab tests and models of the virus’ spike protein mutations.
-
Moderna Announces Supply Agreement with the UK for Additional 60 Million Doses of Moderna’s COVID-19 Vaccine in 2022 and 2023
12/1/2021
Moderna, Inc. (Nasdaq: MRNA), today announced a revised supply agreement with the UK government for up to 60 million doses of Moderna’s COVID-19 vaccine, which may include authorized booster vaccine candidates, with up to 29 million doses expected to be delivered in 2022 and up to 31 million doses expected to be delivered in 2023.
-
Omicron Update: CDC, Biden Advise Urgency
11/30/2021
The CDC has shifted its recommendation on adults getting a booster COVID-19 vaccine to now include everyone ages 18 years and older. -
Early tests of Regeneron’s antibody cocktail show it isn’t as effective against Omicron while a separate tests of Eli Lilly’s antibody cocktail also demonstrated the same.
-
The whole world is watching the news about Omicron, but it’s obvious that it will be a week or two before enough is known about the new variant of concern.
-
Coronavirus (COVID-19) Update: FDA Actively Working to Investigate, Address Potential Impacts of Omicron Variant; Urges Vaccination and Boosters
11/30/2021
As we have with previous emerging COVID-19 variants, the U.S. Food and Drug Administration is actively working with our federal partners, international regulators and medical product companies to quickly address any potential impacts of the new omicron variant on the tools to fight the pandemic.
-
Welcome to the New Reality of Omicron
11/29/2021
The World Health Organization officially declared omicron – aka. B.1.1.529 – a variant of concern (VOC) on Friday. -
Omicron has caused the U.S. to install travel bans against several South African countries while vaccine makers rush to test their vaccines against it. For that news and more, continue reading.
-
Moderna COVID-19 vaccine effective 5 months after 2nd dose
11/29/2021
Kaiser Permanente research in Southern California published Nov. 25, 2021, in The Lancet Regional Health – Americas confirmed high Moderna COVID-19 vaccine effectiveness up to 5 months after the second dose.
-
DaVita Clinical Research Study Indicates Effectiveness of mRNA COVID-19 Vaccines in Dialysis Patients
11/29/2021
Dialysis patients who received mRNA COVID-19 vaccines had a lower risk of COVID-19 diagnosis post-vaccination and were less likely to be hospitalized or die following breakthrough infection than unvaccinated patients, according to a DaVita Clinical Research study published online ahead of print by the Journal of the American Society of Nephrology.
-
Moderna Announces Strategy to Address Omicron (B.1.1.529) SARS-CoV-2 Variant
11/26/2021
Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced updates to its strategy to address SARS-CoV-2 variants of concern, given the emergence of the B.1.1.529 variant.
-
With the Thanksgiving holiday upon us, BioSpace felt it was important to give thanks for some of the positive things that have happened this year. And there are many!
-
Many factors contribute to a community building herd immunity. Are we close to having herd immunity against Covid-19?
-
The U.S. CDC has issued new travel warnings as surges of COVID-19 continue throughout the country and the world. For that and other COVID-19 news, read below.
-
The recommendation comes after a thorough evaluation of both products' effectiveness and safety profiles, presented at the Advisory Committee on Immunization Practices last week.
-
Moderna to Present at Upcoming Investor Conferences in December 2021
11/22/2021
Moderna, Inc. today announced its participation in the following upcoming virtual investor conferences: NASDAQ 45th Investor Conference on Wednesday, December 1st at 9:30 a.m. ET.
-
The U.S. Food and Drug Administration approved COVID-19 vaccine booster shots for all Americans ages 18 and over Friday morning.